In Brief: OTC nizatidine, Zantac 75
This article was originally published in The Tan Sheet
OTC nizatidine, Zantac 75: Whitehall-Robins' nizatidine Rx-to-OTC switch is "approvable," FDA notified the company on Nov. 30. The agency's Nonprescription Drug and Gastrointestinal Drugs Advisory Committees recommended that nizatidine 75 b.i.d. be approved for prevention of meal-induced heartburn at a Sept. 28 meeting ("The Tan Sheet" Oct. 2, p. 13). Glaxo-Wellcome was informed on Oct. 23 by FDA that its heartburn remedy Zantac 75 is "approvable." The nonprescription ranitidine Rx-to-OTC switch received an advisory committee recommendation in July ("The Tan Sheet" July 17, p. 4). The product will be marketed by Warner Wellcome under a joint venture agreement with Glaxo...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC